Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Inclusion Criteria: 1. Voluntarily agree to participate in this study and sign a written informed consent form 2. Age ≥18 years and ≤75 years, regardless of gender 3. Histologically or cytologically confirmed locally advanced (stage IIIB-IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy 4. No prior systemic antineoplastic therapy for advanced/metastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation) 5. Central laboratory-confirmed PD-L1 Tumor Proportion Score (TPS) ≥50% 6. At least one measurable target lesion according to RECIST v1.1 criteria 7. Asymptomatic or locally treated stable brain metastases are allowed. 8. ECOG performance status 0-1 9. Expected survival ≥3 months 10. Adequate organ function Exclusion Criteria: 1. Histological type of small cell lung cancer or mixed small cell lung cancer 2. Prior treatment with any EGFR-TKI or MET-TKI 3. Presence of ALK fusion positive or ROS1 fusion positive 4. Other active malignant tumors (except completely resected carcinoma in situ, basal cell or squamous cell skin cancer, or tumors with no recurrence for ≥3 years after curative treatment) 5. Major surgery within 4 weeks before first dose (except brain metastasis resection, which requires ≥2 weeks); thoracoscopic biopsy or mediastinoscopy is excluded (requires ≥1 week) 6. Require use of strong CYP3A4 inhibitors or inducers within 1 week before first dose or during the study 7. Uncontrolled systemic diseases 8. Cardiac dysfunction: QTcF \>470ms (average of three ECGs) at screening; NYHA functional class ≥3 or LVEF \<50% 9. Dysphagia, active digestive system disease, or history of major gastrointestinal surgery that may affect drug absorption 10. History of acute or chronic pancreatitis or pancreatic surgery 11. Other conditions deemed unsuitable for participation by the investigator